Full Breakdown
The Economic Contradictions of the U.S. Drug Channel
11/18/2025, 8:00:03 PM
Overview of the Current Landscape
The U.S. drug pricing system is facing scrutiny due to significant discrepancies in drug pricing practices, particularly highlighted by the recent analysis of Cigna/Evernorth’s Quallent Pharmaceuticals. This analysis reveals that Quallent's average Average Wholesale Price (AWP) to Wholesale Acquisition Cost (WAC) ratio stands at 1.38x, exceeding the industry standard of 1.20x, with some products reaching a ratio of 2.00x. Such inflated pricing could lead plan sponsors to overpay substantially for generic drugs.
The Role of Pharmacy Benefit Managers
Pharmacy Benefit Managers (PBMs) play a crucial role in this landscape, as they often promote private-label biosimilars that carry higher list prices compared to competing options. Cuban’s Cost Plus Drug Company has introduced Starjemza, a biosimilar of Stelara, priced at 99% below the reference product. This pricing strategy aims to disrupt traditional benefit designs by establishing a cash-pay benchmark that challenges the reliance on rebates.
Global Context of Drug Spending
In a broader context, net drug spending in the U.S. is reported to be in the middle range compared to 12 major countries, accounting for 9% to 21% of total healthcare costs. Despite the perception of high drug costs, U.S. drug spending aligns with global averages when considering both retail and non-retail drugs, net of rebates and discounts. However, the overall healthcare system in the U.S. remains more expensive, complicating comparisons based solely on brand-name drug shares.
Criticism of Alternative Funding Programs
A recent CNBC exposé has raised alarms about alternative funding programs (AFPs) such as PriceMD, Rx Valet, and SHARx, which reportedly circumvent FDA regulations by sourcing specialty drugs from unverified suppliers and potentially illicit online pharmacies. Critics argue that these schemes create confusion and risks for beneficiaries, while also excluding specialty drugs from formularies, effectively leaving patients without coverage for necessary medications.
Official Statements & Responses
Cigna has not yet provided a rebuttal or explanation regarding the findings related to Quallent Pharmaceuticals. Meanwhile, the ongoing discussion surrounding AFPs has prompted calls for accountability and regulatory oversight to prevent dangerous practices that jeopardize patient safety.
Verbatim Quotes
- “If these figures are accurate, it’s yet another reminder: Always check your contract's math.” — Antonio Ciaccia, 46brooklyn Research
- “As I have long argued , it’s long past time to hold AFPs accountable and stop these dangerous workarounds.” — Anonymous Commentator
Conclusion
The current state of the U.S. drug channel reveals significant economic contradictions, particularly in pricing practices and the role of PBMs. As scrutiny increases, stakeholders are urged to reassess their strategies and ensure that drug pricing is transparent and equitable for all beneficiaries. The ongoing debates surrounding AFPs and their implications for patient safety further underscore the need for reform in the healthcare system.
